Differentiation of δ, μ, and κ opioid receptor agonists based on pharmacophore development and computed physicochemical properties
暂无分享,去创建一个
[1] Michal Hušák,et al. The Crystal and Molecular Structure of Butorphanol Hydrogen Tartrate , 1994 .
[2] Ping Huang,et al. Development of a common 3D pharmacophore for δ-opioid recognition from peptides and non-peptides using a novel computer program , 1997, J. Comput. Aided Mol. Des..
[3] Lei Yu,et al. Molecular cloning and functional expression of a mu opioid receptor from rat brain , 1994, Regulatory Peptides.
[4] Gilda H. Loew,et al. Thermodynamics of ligand binding to the cloned δ-opioid receptor , 1996 .
[5] H. Loh,et al. Regulation of opioid receptor activities. , 1999, The Journal of pharmacology and experimental therapeutics.
[6] A Ulloa-Aguirre,et al. Structure-activity relationships of G protein-coupled receptors. , 1999, Archives of medical research.
[7] A. Kastin,et al. Opiate tolerance and dependence: receptors, G-proteins, and antiopiates , 1998, Peptides.
[8] Judith L. Flippen-Anderson,et al. X-Ray crystal structures of potent opioid receptor ligands: etonitazene, cis-(+)-3-methylfentanyl, etorphine, diprenorphine, and buprenorphine , 1994 .
[9] A. Verloop,et al. Development and Application of New Steric Substituent Parameters in Drug Design , 1976 .
[10] P. Pascoe,et al. Perioperative pain management. , 2000, The Veterinary clinics of North America. Small animal practice.
[11] M. Nishi,et al. Primary structures and expression from cDNAs of rat opioid receptor δ‐and μ‐subtypes , 1993 .
[12] D. Ferguson,et al. Molecular docking reveals a novel binding site model for fentanyl at the mu-opioid receptor. , 2000, Journal of medicinal chemistry.
[13] L. Bare,et al. Isolation of a Human κ Opioid Receptor cDNA from Placenta , 1994 .
[14] Marta Filizola,et al. 3D modeling, ligand binding and activation studies of the cloned mouse δ, μ and κ opioid receptors , 1999 .
[15] Jonas Boström,et al. Conformational energy penalties of protein-bound ligands , 1998, J. Comput. Aided Mol. Des..
[16] G. Uhl,et al. Human mu opiate receptor. cDNA and genomic clones, pharmacologic characterization and chromosomal assignment. , 1994, FEBS letters.
[17] A. Lomize,et al. Opioid receptor three-dimensional structures from distance geometry calculations with hydrogen bonding constraints. , 1998, Biophysical journal.
[18] Lakshmi A Devi,et al. Opioids and Their Complicated Receptor Complexes , 2000, Neuropsychopharmacology.
[19] Henry I. Mosberg. Complementarity of δ opioid ligand pharmacophore and receptor models , 1999 .
[20] Marta Filizola,et al. Molecular determinants of non-specific recognition of δ, μ, and κ opioid receptors , 2001 .
[21] H. Villar,et al. Strategies for Indirect Computer-Aided Drug Design , 1993, Pharmaceutical Research.
[22] E Bye,et al. Crystal structures of synthetic analgetics. V. Dextromoramide. , 1976, Acta chemica Scandinavica. Series B: Organic chemistry and biochemistry.
[23] Hugo O. Villar,et al. Quantum mechanical parametrization of a conformationally dependent hydrophobic index , 1992 .
[24] H Weinstein,et al. Comparative modeling and molecular dynamics studies of the delta, kappa and mu opioid receptors. , 1997, Protein engineering.
[25] R. Edwards,et al. Cloning of a delta opioid receptor by functional expression. , 1992, Science.
[26] G H Loew,et al. Evidence for mu1-opioid receptor involvement in fentanyl-mediated respiratory depression. , 1996, European journal of pharmacology.
[27] Marta Filizola,et al. Molecular modeling study of the differential ligand–receptor interaction at the μ, δ and κ opioid receptors , 1999, J. Comput. Aided Mol. Des..
[28] H. Villar,et al. Atom based parametrization for a conformationally dependent hydrophobic index , 1991 .
[29] V. Ananthanarayanan,et al. Homology models of mu-opioid receptor with organic and inorganic cations at conserved aspartates in the second and third transmembrane domains. , 2000, Archives of biochemistry and biophysics.
[30] B. Kieffer,et al. A molecular basis for opiate action. , 1998, Essays in biochemistry.
[31] Juan J. Perez,et al. Characterization of the bioactive form of linear peptide antagonists at the δ‐opioid receptor , 1996 .
[32] C L Brooks,et al. Do active site conformations of small ligands correspond to low free-energy solution structures? , 1998, Journal of computer-aided molecular design.
[33] U. Gether. Uncovering molecular mechanisms involved in activation of G protein-coupled receptors. , 2000, Endocrine reviews.